medigraphic.com
ISSN 1561-2996 (Electronic)
ISSN 0864-0289 (Print)

2021, Number 2

<< Back Next >>

Rev Cubana Hematol Inmunol Hemoter 2021; 37 (2)

Chronic lymphoid leukemia: cytogenetic and molecular aspects

González GS, Lavaut SK

Language: Spanish
References: 25
Page: 1-14
PDF size: 264.22 Kb.


ABSTRACT

Introduction: Chronic B lymphoid leukemia is a lymphoproliferative disorder characterized by the accumulation of small, mature-looking lymphocytes in peripheral blood, bone marrow and lymphoid tissues with a long life span. It has great clinical and genetic variability.
Objective: To describe the cytogenetic and molecular aspects of the disease.
Methods: A review of the literature in English and in Spanish was carried out, in the PubMed website and using the search engine of Google Scholar, for articles published in the last five years. We performed analysis and summary of the reviewed bibliography.
Development: In chronic lymphoid leukemia, frequent cytogenetic alterations are present such as deletion of chromosomes 13q, 11q and 17p, as well as trisomy 12, which together with the knowledge of the mutational status of the gene for the variable region of the immunoglobulin heavy chain and other somatic mutations in different genes, as well as clinical and laboratory variables allows prognostic stratification of patients.
Conclusions: Diagnosis through conventional mitogen-stimulated cytogenetic studies, fluorescence in situ hybridization and gene sequencing allow a better understanding of the biology of the disease, as well as making more personalized therapeutic decisions.


REFERENCES

  1. Emadi A, Law JY. Leucemia linfocítica crónica (LLC). En: Manual MSD. Versión para profesionales. (Actualizado: Dic 2018) (acceso: 20/06/2020) Disponible en: https://www.msdmanuals.com/es/professional/hematolog%C3%ADa-y-oncolog%C3%ADa/leucemias/leucemia-linfoc%C3%ADtica-cr%C3%B3nica-llc

  2. Aitken MJL, Lee HJ, Post SM. Emerging treatment options for patients with p53-pathway-deficient CLL. Ther Adv Hematol. 2019 Dec 5; 10:2040620719891356. DOI: https://10.1177/2040620719891356

  3. García JA, Giraldo P, López J, Ríos E, Sastre JL, Terol MJ, et al. Guía de consenso nacionales para el estudio y tratamiento de los pacientes con leucemia linfocítica crónica. Med Clin (Barc). 2013 Ago;141(4):175.e1–e8. DOI: https://10.1016/j.medcli.2013.04.041

  4. Delgado J, Doubek M, Baumann T, Kotaskova J, Molica S, Mozas P, et al. Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI. Am J Hematol.2017 Abr;92(4):375-80.

  5. Kipps TJ, Stevenson FK, Wu CJ, Croce CM, Packham G, Wierda WG, et al. Chronic lymphocytic leukaemia. Nat Rev Dis Primers. 2017 Ene;3:16096.

  6. BaumannLM, Tarchand G, Morrison VA. The impact of Agent Orange exposure on presentation and prognosis of patients with chronic lymphocytic leukemia. Leuk. Lymphoma. 2014 Ene; 55:63-6.

  7. Yun X, Zhang Y, Wang X. Recent progress of prognostic biomarkers and risk scoring systems in chronic lymphocytic leukemia. Biomark Res. 2020 Sep; 8:40.

  8. Valdespino VM. Leucemia linfocítica crónica de linfocitos B: un modelo personalizado de valoración clínica y molecular. Rev Hematol Mex. 2014;15(3):103-21.

  9. Autore F, Strati P, Laurenti L, Ferrajoli A. Morphological, immunophenotypic, and genetic features of chronic lymphocytic leukemia with trisomy 12: a comprehensive review. Haematologica. 2018 May;103(6):931-8.

  10. Parker H, Rose MJJ, Parker A, Chaplin T, Wade R, Gardiner A, et al. 13q deletion anatomy and disease progression in patients with chronic lymphocytic leukemia. Leukemia. 2011 Mar;25(3):489-97.

  11. Puiggros A, Blanco G, Espinet B. Genetic Abnormalities in Chronic Lymphocytic Leukemia: Where We Are and Where We Go. Biomed Res Int. 2014 May; 2014:435983.

  12. Rampazzo E, Bojnik E, Trentin L, Bonaldi L, Del Bianco P, Frezzato F, et al. Role of miR-15a/miR-16-1 and the TP53 axis in regulating telomerase expression in chronic lymphocytic leukemia. Haematologica. 2017 Jul;102(7):e253-e6

  13. MaESK. Recurrent Cytogenetic Abnormalities in Non-Hodgkin’sLymphoma and Chronic Lymphocytic Leukemia. Methods Mol Biol.2017; 1541:270-91.

  14. Quijada M, Hernández M, Alonso V, Rodríguez AE, García I, Martín M, et al. CRISPR/Cas9-generated models uncover therapeutic vulnerabilities of del(11q) CLL cells to dual BCR and PARP inhibition. Leukemia. 2020 Ene;34(6):1599-612.

  15. Strati P, Keating MJ, O’Brien SM, Ferrajoli A, Burger J, Faderl S, et al. Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion. Haematologica. 2014 Ago;99(8):1350-5.

  16. Campo E, Cymbalista F, Ghia P, Jäger U, Pospisilova S, Rosenquist R, et al. TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics. Haematologica. 2018 Dic;103(12):1956-68.

  17. González I, Hernández M, Rodríguez AE, Sanzo C, Aventín A, Peligros A, et al. A high proportion of cells carrying trisomy 12 is associated with a worse outcome in patients with chronic lymphocytic leukemia. Hematol Oncol. 2016 Jun;34(2):84–92.

  18. Baliakas P, Jeromin S, Iskas M, Puiggros A, Plevova K, Nguyen-Khac F, et al. Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact. Blood. 2019 Mar;133(11):1205-16.

  19. Liu P, Xu B, Shen W, Zhu H, Wu W, Fu Y, et al. Dysregulation of TNFalpha-induced necroptotic signaling in chronic lymphocytic leukemia: suppression of CYLD gene by LEF1. Leukemia. 2012 Ene; 26(6):1293-300.

  20. Medves S, Auchter M, Chambeau L, Gazzo S, Poncet D, Grangier B, et al. A high rate of telomeric sister chromatid exchange occurs in chronic lymphocytic leukaemia B-cells. Br J Haematol. 2016 Jul;174(1):57-70.

  21. Hernández JA, González I. Genetic Heterogeneity in Chronic Lymphocytic Leukemia: What Can Conventional Cytogenetics Add? Acta Haematol. 2017;138:31-2.

  22. Guieze R, Robbe P, Clifford R, Guibert S, Pereira B, Timbs A, et al. Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL. Blood. 2015 Oct;126(18):2110-7.

  23. Rosati E, Baldoni S, De Falco F, Del Papa B, Dorillo E, Rompietti C, et al NOTCH1 Aberrations in Chronic Lymphocytic Leukemia. Front Oncol. 2018 Jun; 8:229.

  24. Fabbri G, Rasi S, Rossi D, Trifonov V, Khiabanian H, Ma J, et al. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med. 2011 Jul;208(7):1389-401.

  25. TeRaaGD, Derks IA, Navrkalova V, Skowronska A, Moerland PD, van Laar J, et al. The impact of SF3B1 mutations in CLL on the DNA damage response. Leukemia. 2015 May;29(5):1133-42.




2020     |     www.medigraphic.com